Sugi Predict

Sugi Predict / Compounds / SCHEMBL205844

SCHEMBL205844

SCHEMBL205844

COC(=O)N[C@H](C(=O)O)C1CCOCC1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ PYGL P06737 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ AAK1 Q2M2I8 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ MMP13 P45452 8/20 0.35
▸ MMP2 P08253 7/20 0.35
▸ MMP3 P08254 7/20 0.35
▸ MMP1 P03956 6/20 0.35
▸ MMP7 P09237 4/20 0.35
▸ MMP9 P14780 3/20 0.35
▸ MMP8 P22894 2/20 0.35
▸ MAPK1 P28482 1/20 0.35
▸ MME P08473 1/20 0.32
▸ MMP14 P50281 1/20 0.32
▸ ADAM17 P78536 1/20 0.32
▸ FPR2 P25090 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2708029 1.00 PYGL (0.38) PYGLCYP2C9AAK1ALDH1A1MMP13
SCHEMBL204476 1.00 PYGL (0.38) PYGLCYP2C9AAK1ALDH1A1MMP13
SCHEMBL240248 0.90 PYGL (0.33) PYGLCYP2C9AAK1ALDH1A1MAPK1
SCHEMBL241410 0.90 PYGL (0.33) PYGLCYP2C9AAK1ALDH1A1MAPK1
SCHEMBL240247 0.90 PYGL (0.33) PYGLCYP2C9AAK1ALDH1A1MAPK1
SCHEMBL19318662 0.90 PYGL (0.33) PYGLCYP2C9AAK1ALDH1A1MAPK1
Valine SCHEMBL1806500 0.89 SLC7A5 (0.41) PYGLCYP2C9AAK1ALDH1A1MMP13
SCHEMBL206034 0.87 MMP2 (0.37) PYGLAAK1MMP13MMP2MMP3
SCHEMBL193724 0.87 MMP2 (0.37) PYGLAAK1MMP13MMP2MMP3
SCHEMBL17327255 0.87 AAK1 (0.37) PYGLCYP2C9AAK1ALDH1A1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 459 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3438106-A1 ANTI-VIRAL COMPOUNDS AbbVie Ireland Unlimited Company (IE) 2019-02-06 — — EP claimed
US-20190015402-A1 Anti-Viral Compounds ABBVIE INC. (US) 2019-01-17 — — US claimed
EP-3445367-B1 HEPATITIS C VIRUS INHIBITORS MERCK SHARP & DOHME LLC (US) 2023-11-22 — — EP disclosed
US-20230285378-A1 Anti-Viral Compounds ABBVIE INC. (US) 2023-09-14 — — US disclosed
US-20210053981-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. 2021-02-25 — — US disclosed
EP-3778606-A2 CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2021-02-17 — — EP disclosed
CN-106588890-B Antiviral compounds 吉利德制药有限责任公司 2020-11-27 — — CN disclosed
US-10807990-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2020-10-20 — — US disclosed
US-10800789-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2020-10-13 — — US disclosed
EP-3699176-A2 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-08-26 — — EP disclosed
EP-3699176-A2 ANTIVIRAL COMPOUNDS Gilead Pharmasset LLC (US) 2020-08-26 — — EP disclosed
WO-2009102633-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-20 — — WO disclosed
WO-2009102694-A1 HETEROCYCLIC DERIVATIVES AS HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2009-08-20 — — WO disclosed
US-20090202483-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-08-13 — — US disclosed
US-20090202483-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-08-13 — — US disclosed
US-20090202478-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-08-13 — — US disclosed
US-20090202478-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2009-08-13 — — US disclosed
US-20090068140-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2009-03-12 — — US disclosed
US-20080050336-A1 Hepatitis C Virus Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2008-02-28 — — US disclosed
WO-2008021927-A2 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2008-02-21 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230285378-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PYGL 88/4885CYP2C9 3780/4885AAK1 2181/4885
US-20090202478-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS PYGL 2/4885CYP2C9 2585/4885AAK1 3729/4885
US-20080050336-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS PYGL 2/4885CYP2C9 2585/4885AAK1 3729/4885
US-20090068140-A1 HEPATITIS C VIRUS INHIBITORS HAVCR2, PYGL, HCCS PYGL 2/4885CYP2C9 2585/4885AAK1 3729/4885
US-10807990-B2 Antiviral compounds MAVS, EIF2AK2, SARS1 PYGL 844/4885CYP2C9 3743/4885AAK1 3549/4885
US-20190015402-A1 Anti-Viral Compounds HAVCR2, EIF2AK2, MAVS PYGL 88/4885CYP2C9 3780/4885AAK1 2181/4885
US-20090202483-A1 Hepatitis C Virus Inhibitors HAVCR2, PYGL, HCCS PYGL 2/4885CYP2C9 2585/4885AAK1 3729/4885
US-10800789-B2 Antiviral compounds MAVS, EIF2AK2, SARS1 PYGL 844/4885CYP2C9 3743/4885AAK1 3549/4885
US-20210053981-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, SARS1 PYGL 844/4885CYP2C9 3743/4885AAK1 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.